Cardiac Troponin Test (Troponin I & T)

Cardiac Troponin — scientific infographic poster

Cardiac troponin (cTnI and cTnT) is the gold-standard biomarker for diagnosing acute myocardial infarction. Released from cardiomyocytes when the cell membrane is disrupted, it combines high sensitivity — it detects even minor myocardial injury — with high cardiac specificity, because the cardiac isoforms are structurally distinct from skeletal muscle troponin. The arrival of high-sensitivity troponin (hs-cTn) assays transformed the emergency evaluation of chest pain, making 0h/1h and 0h/2h rapid rule-in / rule-out algorithms possible where earlier assays needed six hours or more.

❤️ Interactive Visualization The Heart & Circulation — watch a blood cell make the loop Trace a blood cell through all four chambers and both circuits, with a live ECG, chamber pressures, and an exercise mode. Launch →

Table of Contents

  1. What the Cardiac Troponin Test Measures
  2. Biochemistry of the Troponin Complex
  3. Why Troponin Testing Is Ordered
  4. How the Test Is Performed
  5. Troponin I vs. Troponin T: Differences
  6. Reference Ranges and Result Interpretation
  7. The Troponin Rise-and-Fall Pattern
  8. Rapid Rule-In and Rule-Out Algorithms
  9. The HEART Score
  10. The Five Types of Myocardial Infarction
  11. Conditions That Elevate Troponin
  12. Non-Coronary Causes in Depth
  13. High-Sensitivity Troponin (hs-cTn)
  14. How to Reduce Cardiac Risk
  15. Limitations of Troponin Testing
  16. Key Research Papers
  17. Connections
  18. Featured Videos

What the Cardiac Troponin Test Measures

Cardiac troponin is a protein complex found exclusively in heart muscle cells (cardiomyocytes). It plays a central role in regulating the contraction of the heart by controlling the interaction between actin and myosin, the two proteins that generate the mechanical force of heartbeat. The troponin complex has three subunits: troponin C (which binds calcium), troponin I (which inhibits contraction in the resting state), and troponin T (which anchors the complex to tropomyosin on the actin filament).

In a healthy heart, troponin remains inside cardiomyocytes. When heart muscle cells are damaged or die -- as occurs during a myocardial infarction, myocarditis, or significant cardiac stress -- the cell membranes break down and troponin leaks into the bloodstream. Because cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are structurally distinct from their skeletal muscle counterparts, laboratory assays can detect them with high cardiac specificity. Even tiny amounts of myocardial injury produce measurable troponin elevation well before symptoms escalate or electrocardiogram changes appear.

Troponin testing has become the gold-standard biomarker for diagnosing acute myocardial infarction (heart attack) and for risk-stratifying patients presenting with chest pain. The advent of high-sensitivity troponin (hs-cTn) assays in the 2010s further transformed cardiac emergency medicine by detecting injury at concentrations 10 to 100 times lower than conventional assays.

How Troponin Became the Standard

Troponin entered routine clinical use as a cardiac biomarker in the 1990s and rapidly displaced CK-MB (the MB isoform of creatine kinase), which had been the previous standard but was also present in skeletal muscle and therefore far less cardiac-specific. The 2000 ESC/ACC consensus document redefined myocardial infarction around the new marker: any troponin elevation above the 99th percentile of a healthy reference population, accompanied by a rise and/or fall pattern and evidence of ischemia. That document became the first "Universal Definition of Myocardial Infarction," and it has been revised three times since — in 2007, 2012, and 2018.

The two cardiac-specific isoforms measured in clinical practice are distinguished from their skeletal-muscle counterparts by structural features that the assay antibodies target directly:

Both are measured with highly specific monoclonal antibodies that do not cross-react with skeletal muscle isoforms under normal conditions — which makes the test cardiac-specific, not merely cardiac-sensitive. It is worth being precise about what that specificity does and does not buy: troponin identifies myocardial cell injury or death, but it does not identify the cause of that injury. Coronary atherosclerosis, cardiomyopathy, myocarditis, pulmonary embolism, and sepsis all produce the same signal. Sorting out which one is in front of you requires clinical history, the ECG, echocardiography, and where appropriate coronary angiography.

Biochemistry of the Troponin Complex

The troponin complex is a trimeric regulatory protein embedded in the thin filament of striated muscle, sitting at the core of the calcium-regulated actin-myosin contraction cycle. Each of the three subunits has a distinct structural and functional role:

The Contraction Cycle

When intracellular calcium rises during an action potential, calcium binds TnC's regulatory site II. The resulting conformational change causes TnC to grab TnI's inhibitory domain, releasing TnI from actin. Tropomyosin then shifts and exposes the myosin-binding sites on actin, permitting cross-bridge cycling and contraction. When calcium is pumped back into the sarcoplasmic reticulum by SERCA, TnC releases its calcium, TnI rebinds actin, tropomyosin slides back over the myosin-binding sites, and the muscle relaxes.

Why Troponin Leaks in Two Phases

Ischemia lasting beyond roughly 20–40 minutes produces irreversible cardiomyocyte injury and disruption of the sarcolemmal membrane. Troponin then escapes in two distinct waves, and this is what gives the blood test its characteristic shape:

That slow second phase is diagnostically valuable: a patient who presents days after an episode of chest pain may still have measurable troponin from the original event, allowing a subacute MI to be identified retrospectively.

Why Troponin Testing Is Ordered

Cardiac troponin testing is ordered in a wide range of clinical situations:

How the Test Is Performed

Cardiac troponin is measured from a standard venous blood draw. No fasting is required. The sample is sent to the clinical laboratory immediately -- troponin testing in emergency settings is typically processed as a STAT (urgent) order with results available within 30-60 minutes in most hospital laboratories running on-site analyzers.

Because troponin rises progressively after cardiac injury rather than instantly, serial sampling is essential for diagnosis. Most current rapid rule-in/rule-out protocols use either:

Point-of-care (POC) troponin devices are also available for bedside testing in pre-hospital settings or resource-limited environments, though laboratory-based assays remain the gold standard for sensitivity and precision.

Troponin I vs. Troponin T: Differences

Both cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are equally accepted as diagnostic markers for myocardial injury. They are structurally distinct proteins encoded by different genes, and their clinical performance characteristics differ slightly:

Cardiac Troponin I (cTnI):

Cardiac Troponin T (cTnT):

For practical purposes in non-skeletal-muscle-disease patients, cTnI and cTnT perform equivalently and either is acceptable for AMI diagnosis and risk stratification.

Reference Ranges and Result Interpretation

Troponin reference ranges are assay-specific and vary between laboratories. The universal diagnostic threshold for acute myocardial injury is the 99th percentile of a healthy reference population (also called the upper reference limit or URL). Any troponin elevation above the 99th percentile URL is considered abnormal and indicates myocardial injury.

Typical conventional troponin ranges (exact values differ by assay platform):

A note on the hs-cTnT numbers above. The 19 / 22 / 14 ng/L set is the FDA-cleared US package-insert value for the fifth-generation Elecsys hs-cTnT assay. The same assay is sold outside the United States with a lower published set — approximately 14 ng/L overall, about 9 ng/L for women and about 15.5 ng/L for men — and the European rapid-triage algorithms described below were validated against those lower figures. Both sets are legitimate; they belong to different regulatory versions of one assay. The practical consequence is that a troponin result must be read against the reference limits printed on the report by the laboratory that ran it, never against a number remembered from elsewhere. The 99th percentile itself, despite periodic arguments for higher cutoffs, remains the best-established diagnostic threshold in the field.

Results must always be interpreted in clinical context:

Why the Reference Range Differs by Sex

Women consistently have lower 99th percentile troponin concentrations than men, for both hs-cTnT and hs-cTnI. Applying a sex-specific URL rather than one combined number does two things at once:

The 2018 Fourth Universal Definition of Myocardial Infarction recommends sex-specific URLs wherever they have been validated for the assay in use. A laboratory that reports a single combined threshold is, in effect, reproducing the same under-diagnosis of women that existed before high-sensitivity assays arrived.

Why the Reference Range Rises With Age

The 99th percentile climbs substantially with age even among people considered healthy. This is not a laboratory artifact — it reflects genuine subclinical myocardial injury accumulating from hypertension, silent coronary disease, left ventricular hypertrophy, and early kidney impairment. Age-specific percentile tables have been published for some assays. Clinically, the implication is that an 82-year-old with an hs-cTnT of 20 ng/L may be sitting at a stable personal baseline rather than having an acute event, and only the rise-and-fall pattern across serial draws can tell the two apart.

The Rise/Fall (Delta) Criterion

A single value above the 99th percentile establishes myocardial injury. It does not establish acute myocardial infarction, which additionally requires a dynamic change indicating an evolving process. The key delta thresholds for hs-cTnT are:

Back to Table of Contents

The Troponin Rise-and-Fall Pattern

The characteristic biokinetic pattern of troponin in acute MI is a rise-and-fall curve that reflects the release and gradual clearance of troponin from damaged cardiomyocytes. Understanding this pattern is essential for interpreting serial results:

The delta change (absolute or relative change between serial measurements) is a critical diagnostic concept. Current European Society of Cardiology (ESC) guidelines define the following delta thresholds for hs-cTnT rule-in:

Rapid Rule-In and Rule-Out Algorithms

The 2020 ESC guidelines for acute coronary syndromes without persistent ST-segment elevation define three validated high-sensitivity troponin algorithms for emergency chest-pain evaluation. All of them replace the old practice of holding a patient for six or more hours of serial draws before a decision could be made.

The 0h/1h Algorithm (Preferred)

Two hs-cTn measurements are taken: one at presentation and one exactly one hour later. Patients then fall into one of three zones. The figures below are for hs-cTnT on the Roche Elecsys platform, as validated in the TRAPID-AMI multicenter study of 1,282 patients:

The specific ng/L values are assay-dependent and are not transferable. The thresholds above apply to Roche Elecsys hs-cTnT; Abbott and Siemens hs-cTnI platforms have their own separately validated numbers, and using one assay's cut-points with another assay's results is a serious error.

The 0h/2h Algorithm

An alternative for departments where a precise one-hour re-draw is logistically difficult. Two samples are taken at presentation and two hours later. Rule-out requires both values below the assay-specific low threshold with a change below the absolute cut-point; rule-in requires a markedly elevated presenting value or a large 2-hour delta. Negative predictive value is comparable at roughly 99%, but rule-out efficiency is lower — about half of patients are dischargeable, versus roughly three in five with the 0h/1h approach.

The 0h/3h Algorithm

The original rapid algorithm, still used where one-hour logistics have not been established. It applies the fixed 99th percentile threshold plus a significant delta (a relative change above 20%, or an absolute change above the assay's minimum significant difference) across three hours. Negative predictive value is around 99%, but the patient occupies an emergency department bed three times as long as under the 0h/1h protocol.

Back to Table of Contents

The HEART Score

Troponin is one input, not the whole decision. The HEART score is a validated five-component clinical decision tool — History, ECG, Age, Risk factors, Troponin — that scores each element 0, 1, or 2 for a total of 0 to 10, and sorts chest-pain patients into three risk bands by their 30-day rate of major adverse cardiac events (MACE):

The original prospective validation across four Dutch hospitals confirmed that the score outperformed the older TIMI and GRACE scores for this specific question — which undifferentiated chest-pain patient can safely go home.

The Five Types of Myocardial Infarction

The Fourth Universal Definition of Myocardial Infarction classifies MI into five types by pathophysiology, not by troponin magnitude. Two patients can have identical troponin values and need completely different treatment, so this classification carries real therapeutic weight.

Type 1 — Atherosclerotic Plaque Event

Spontaneous MI caused by atherosclerotic plaque rupture, erosion, or fissuring with intraluminal thrombus formation, leading to acute coronary occlusion or sharply reduced coronary flow. This is the classic heart attack, presenting as either STEMI or NSTEMI. Treatment is urgent revascularization — percutaneous coronary intervention preferred — plus dual antiplatelet therapy, anticoagulation, a high-intensity statin, an ACE inhibitor or ARB, and a beta-blocker.

Type 2 — Supply-Demand Mismatch

Myocardial injury caused by something other than plaque disruption, in which oxygen demand outstrips supply. Troponin rises and falls as it does in Type 1, but coronary angiography reveals no culprit lesion. Common triggers include:

Management of Type 2 MI centers on correcting the underlying condition. The benefit of antiplatelet and anticoagulant therapy here is much less well established than in Type 1, and reflexively treating a Type 2 event as though it were a Type 1 can do harm — particularly in a bleeding or septic patient.

Types 3, 4, and 5

The higher multiples required for Types 4a and 5 exist because both procedures cause some myocardial injury by design; the threshold has to clear that expected background before a procedural infarction can be called.

Back to Table of Contents

Conditions That Elevate Troponin

While troponin elevation is most strongly associated with acute MI, it can also be elevated in a broad range of other conditions. Clinicians must consider these alternatives -- sometimes called "type 2 MI" or non-ischemic troponin elevation -- when evaluating a positive result:

Primary cardiac causes:

Non-cardiac causes (secondary myocardial injury):

Back to Table of Contents

Non-Coronary Causes in Depth

Any condition that injures cardiomyocytes will raise troponin, whether or not a coronary artery is involved. The list above is the quick reference; what follows is the detail that matters when a troponin comes back positive and the coronary arteries turn out to be clean.

Myocarditis

Inflammation of the myocardium arising from viral infection (coxsackievirus B, adenovirus, parvovirus B19, influenza, SARS-CoV-2), autoimmune processes (giant cell myocarditis, eosinophilic myocarditis), or toxic exposures (anthracyclines, immune checkpoint inhibitors). Troponin can be markedly elevated, and the ECG may show diffuse ST elevation that mimics a STEMI closely enough to send a patient to the catheterization laboratory. The angiogram shows normal or non-obstructive arteries. Cardiac MRI with late gadolinium enhancement is the key diagnostic tool, showing a patchy, often subepicardial pattern that does not follow a coronary territory.

Pulmonary Embolism

Acute massive or submassive pulmonary embolism causes abrupt right ventricular pressure overload. The RV free wall, which is normally perfused at low pressure and has little reserve, sustains subendocardial ischemia when intracavitary pressure rises suddenly. Troponin elevation in pulmonary embolism independently predicts 30-day mortality and is built into risk-stratification tools such as the PESI and simplified PESI scores. In a hemodynamically unstable patient, an elevated troponin is one of the findings that pushes toward systemic thrombolysis or catheter-directed therapy rather than anticoagulation alone.

Acute Decompensated Heart Failure

Both acute and chronic heart failure are associated with troponin elevation. During acute decompensation, cardiomyocyte injury comes from several directions at once: a raised left ventricular end-diastolic pressure compresses subendocardial perfusion, catecholamine excess drives demand up, and neurohormonal activation adds further stress. Chronic low-level troponin elevation is a powerful independent predictor of mortality in both HFrEF and HFpEF — serial hs-cTnT measurement in two large randomized heart-failure trial populations showed that both the baseline concentration and its change over time carried prognostic information beyond natriuretic peptides.

Takotsubo (Stress) Cardiomyopathy

Also called apical ballooning syndrome or broken heart syndrome. A massive catecholamine surge — emotional shock, severe physical stress, the post-surgical state — produces a transient wall-motion abnormality with ballooning of the left ventricular apex and preserved or hyperdynamic basal contraction, giving the characteristic "octopus pot" shape on ventriculography that named the syndrome. Troponin rises, though usually to a lower peak than an equivalent-territory STEMI would produce, and the disproportion between a modest troponin and a large wall-motion abnormality is itself a diagnostic clue. Coronary angiography shows no obstructive disease, and ejection fraction typically recovers within four to six weeks.

Sepsis-Induced Cardiomyopathy

Direct cardiomyocyte injury from circulating cytokines (TNF-alpha, IL-1beta, IL-6), endotoxin, reactive oxygen species, and nitric oxide produces a reversible myocardial depression in an estimated 10–50% of septic patients. Troponin elevation in sepsis is an independent predictor of ICU mortality. cTnI is generally the more interpretable marker in this setting, because cTnT tends to be disproportionately elevated when the acute kidney injury that so often accompanies sepsis alters its clearance.

Chronic Kidney Disease and Dialysis

Both cTnI and cTnT run chronically elevated in chronic kidney disease. The cause is a combination of reduced clearance, uremia-mediated cardiomyocyte injury, left ventricular hypertrophy, and a genuinely high prevalence of subclinical coronary disease — it is not simply a laboratory artifact, and the elevation carries real prognostic weight. cTnT tends to be proportionally more elevated than cTnI in this population. In dialysis patients the absolute number is nearly uninterpretable on its own; troponin must be measured serially (presentation and 3–6 hours) so that a dynamic change can be detected against the patient's own elevated baseline.

Skeletal Muscle Disease and Rhabdomyolysis

This is the one situation where the choice of assay changes the answer, and it is easy to get backwards. Severely diseased or regenerating skeletal muscle — Duchenne muscular dystrophy, polymyositis, rhabdomyolysis — re-expresses cardiac troponin T isoforms, producing genuinely elevated cTnT with no cardiac injury at all. cTnI does not share this behavior. In a patient with a myopathy and a raised cTnT but a normal ECG and no cardiac symptoms, measuring cTnI on a different platform is the fastest way to resolve the question.

Other Causes

Back to Table of Contents

High-Sensitivity Troponin (hs-cTn)

High-sensitivity cardiac troponin (hs-cTn) assays represent a major technological advance over conventional troponin assays. The key differences:

The adoption of hs-cTn has increased the diagnosis of MI -- particularly in women and patients presenting atypically -- while simultaneously allowing many patients with chest pain to be safely discharged faster with a definitive rule-out rather than extended observation.

What Officially Makes an Assay "High-Sensitivity"

The generation of a troponin assay is not defined by a particular technology but by two analytical performance criteria set out by the International Federation of Clinical Chemistry (IFCC):

The imprecision criterion matters as much as the detection criterion. An assay that can technically report very low numbers but scatters them by 20% run to run cannot support a rule-out decision based on a 3 ng/L change; the whole 0h/1h approach depends on the assay being able to distinguish a small real change from its own noise. The second criterion produces the conceptual shift: because troponin is now measurable at physiological background levels in nearly everyone, clinicians can track a dynamic change from an individual's own baseline instead of waiting for a threshold to be crossed from "undetectable."

Major Validated Platforms

Before high-sensitivity assays, troponin was undetectable at presentation in most NSTEMI patients, and confirming a rise took serial draws at 0, 3, and 6 hours. The 0h/1h algorithm compresses that to a decision inside two hours for roughly three in five patients — the single largest change in emergency chest-pain practice in thirty years. The corresponding hazard is that assay thresholds are not interchangeable: a hospital switching platforms must re-derive its cut-points, and published guidance exists specifically for institutions making that transition.

Back to Table of Contents

How to Reduce Cardiac Risk

For patients who have experienced a troponin-positive event or who are at elevated cardiovascular risk, the following evidence-based strategies reduce future myocardial injury and cardiac events:

Lifestyle Foundations

Targeted Nutritional Support

Medical Management After AMI

For patients who have had a confirmed MI with troponin elevation, guideline-directed medical therapy typically includes dual antiplatelet therapy, high-intensity statin therapy, ACE inhibitors or ARBs (especially with reduced ejection fraction), beta-blockers (in the acute setting and for reduced ejection fraction), and aldosterone antagonists when indicated. These medications have robust evidence for reducing recurrent MI, heart failure, and death.

Limitations of Troponin Testing

Back to Table of Contents

Key Research Papers

Every citation below was checked against the PubMed record on 25 July 2026; the title, journal, volume, and pages match the linked PMID.

Guidelines and Definitions

  1. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–2264. PMID: 30153967
  2. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. PMID: 32860058
  3. Januzzi JL Jr, Mahler SA, Christenson RH, et al. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;73(9):1059–1077. PMID: 30798981

Rapid Rule-Out Algorithms and Early Diagnosis

  1. Mueller C, Giannitsis E, Christ M, et al. Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T (TRAPID-AMI). Ann Emerg Med. 2016;68(1):76–87. PMID: 26794254
  2. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361(9):858–867. PMID: 19710484
  3. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361(9):868–877. PMID: 19710485
  4. Body R, Carley S, McDowell G, et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol. 2011;58(13):1332–1339. PMID: 21920261
  5. Shah AS, Anand A, Sandoval Y, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet. 2015;386(10012):2481–2488. PMID: 26454362
  6. Backus BE, Six AJ, Kelder JC, et al. A prospective validation of the HEART score for chest pain patients at the emergency department. Int J Cardiol. 2013;168(3):2153–2158. PMID: 23465250

Assay Characteristics and Reference Limits

  1. Apple FS, Collinson PO; IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58(1):54–61. PMID: 21965555
  2. Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56(2):254–261. PMID: 19959623
  3. Sandoval Y, Apple FS, Saenger AK, et al. 99th Percentile Upper-Reference Limit of Cardiac Troponin and the Diagnosis of Acute Myocardial Infarction. Clin Chem. 2020;66(9):1167–1180. PMID: 32871000
  4. Hammarsten O, Fu ML, Sigurjonsdottir R, et al. Troponin T percentiles from a random population sample, emergency room patients and patients with myocardial infarction. Clin Chem. 2012;58(3):628–637. PMID: 22258764

Troponin Beyond Acute MI

  1. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22):2503–2512. PMID: 21139111
  2. Masson S, Anand I, Favero C, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012;125(2):280–288. PMID: 22139751
  3. Jaffe AS, Vasile VC, Milone M, et al. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol. 2011;58(17):1819–1824. PMID: 21962825

Risk Reduction After a Troponin-Positive Event

  1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11–22. PMID: 30415628
  2. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts (PREDIMED). N Engl J Med. 2018;378(25):e34. PMID: 29897866

Live PubMed Searches

  1. High-sensitivity troponin and acute MI diagnosis
  2. 0h/1h troponin rule-out protocol (ESC guidelines)
  3. Troponin rapid rule-out algorithm in the emergency department
  4. Cardiac troponin I vs. T in acute coronary syndrome
  5. Non-cardiac causes of troponin elevation
  6. Type 2 myocardial infarction and supply-demand mismatch
  7. Sex-specific troponin thresholds and women's MI diagnosis
  8. Troponin elevation in chronic kidney disease
  9. hs-cTn as a community cardiovascular risk biomarker
  10. Troponin in myocarditis diagnosis and prognosis
  11. Fourth Universal Definition of MI and troponin
  12. HEART score and chest pain risk stratification

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents